B of A Securities Upgrades Editas Medicine to Buy, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has upgraded Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and raised the price target from $13 to $15.
August 08, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has upgraded Editas Medicine from Neutral to Buy and increased the price target from $13 to $15.
The upgrade from Neutral to Buy and the raised price target from $13 to $15 by B of A Securities is likely to positively impact Editas Medicine's stock price in the short term. Analyst upgrades often lead to increased investor confidence and buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100